Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Bone Marrow Transplantation|November 18, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impactMagdalena Corona, Samantha Brown, Kai Rejeski, et al.
Blood Advances|November 21, 2022
Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantationMichael Scordo, Leah J Gilbert, Danielle M Hanley, et al.
Blood Advances|July 23, 2021
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformationOscar B Lahoud, Sean M Devlin, Molly A Maloy, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Bone Marrow Transplantation|April 28, 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplantMaria Sola, Valkal Bhatt, Meighan Palazzo, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
British Journal of Haematology|April 22, 2020
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphomaSairah Ahmed, Nilanjan Ghosh, Kwang W Ahn, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Pageof 9